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Introduction: Incidence of high-grade cervical lesions (HGCL) caused by human 
papillomavirus (HPV) has declined in the U.S following the introduction of the HPV vaccine in 
2006. However, disparities in HPV cervical infection and subsequent sequelae by race, ethnicity 
and income continue to persist. The purpose of this analysis was to identify spatial areas with 
significantly elevated HGCL burden in Connecticut, and determine socioeconomic 
characteristics associated with high incidence clusters.  
Methods: Data from statewide surveillance in Connecticut for cervical intraepithelial neoplasia 
grades 2, 2/3, 3 and adenocarcinoma in situ (CIN 2+) from 2008-2016 were used for this 
analysis. Spatial analyses were performed using SaTScan v9.6 to identify significant clusters of 
HGCLs by census tract among women age 21-39 years across aggregated year groups from 
2008–2010, 2011–2013, and 2014–2016. Four separate mixed effects models with varying 
sociodemographic covariates were constructed to assess the fit of the model to the number of 
HGCL cases per census tract. The likelihood of the predicted incidence for each model was used 
to calculate the Deviance Information Criterion (DIC), which balances goodness of fit and model 
complexity. 
Results: From 2008–2016, incidence of HGCLs declined, particularly in women aged 20–29. 
Spatial analyses identified four significant clusters of HGCLs over time. These clusters varied in 
time, number of census tracts, as well as racial, ethnic and economic composition. The most 
recent cluster of HGCL, located in south central Connecticut among women aged 30–39, 
displayed significantly higher proportions Black, Hispanic and below poverty populations 
compared to the rest of the state. The proportion of Hispanic individuals per census tract was the 
most significant predictor of the number of HGCL cases.  
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Conclusions: The decline in HGCL incidence overall and among young women may suggest 
HPV vaccine impact in CT. The differences in location and socioeconomic composition of 
clusters suggest there are differences in incidence of HGCLs between neighborhoods of varying 
socioeconomic statuses. The relevant nature of ethnicity in predicting HGCL incidence may be 
indicative of a cultural disparity in the health coverage of Hispanic women in CT. The disparities 
in racial, ethnic and income characteristics in census tracts with high incidence of HGCLS 
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Human papillomavirus (HPV) is the most common sexually transmitted infection in the 
US with an estimated 79 million prevalent cases prior to vaccine introduction in 20061. Many 
infections are asymptomatic and transient, but persistent infection with a high-risk HPV type is a 
well-established necessary cause of cervical cancer2. Two high-risk types, HPV 16 and 18, are 
responsible for 70% of cervical cancers. Along the continuum to carcinoma, HPV infections also 
cause high-grade cervical lesions (HGCL) that affect nearly 500,000 women in US annually, of 
which ~50% are caused by high-risk types HPV 16/183. In addition to being a precursor to 
invasive disease, HGCL are an important public health consideration for several reasons 
including high disease burden, costs, and associated health care utilization and psychological 
distress4, 5, 6.  
Differences by race, ethnicity, and income exist throughout the natural history of cervical 
HPV infections. National prevalence studies show that HPV infections are most common in 
black and low-income women7, 8, 9. Previous work has demonstrated disparities by area-based 
measures of race, ethnicity, and poverty in HGCL10. Disparities also pervade the continuum of 
the ‘cancer disparities grid’ for cervical cancer including diagnosis, treatment, and survival11.  
Specifically, women living in poverty and racial/ethnic minorities continue to bear a 
disproportionate burden of incidence and mortality despite the decrease in rates that has resulted 
from widespread cervical cancer screening12, 13, 14, 15, 16, 17. 
Differences by race, ethnicity, and income that are described as health disparities may 
reflect more complex processes and social inequities18. Observable individual characteristics, 
such as race, may signal contextual or geographic factors that are more difficult to measure11. 
Contextual factors are social, cultural, political, and economic characteristics such as poverty, 
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discrimination, racism, sex ratios, interpersonal networks, and residential segregation that differ 
between racial and ethnic groups and likely contribute to persistent health disparities19. Other 
factors may reflect the geographic context, that is, characteristics that operate at the level of 
place such as neighborhoods. These factors may include the built environment, access to health 
services, and community characteristics with known impacts on health outcomes. Previous 
research had displayed geographic distribution of cervical cancer at the county level in the 
United States, with spatial clustering of cervical cancer mortality related to high proportion black 
population, low socioeconomic status and low health care coverage20,21,22. 
Health disparities observed across incidence of HPV-related disease, specifically HGCLs, 
may be further understood through geospatial analyses that can provide insight into factors 
relating to location that may be driving health disparities. This, in turn, can identify areas at the 
local level for targeted interventions. These types of analyses are particularly salient for HPV-
related diseases as identifying particular geographic areas where there may be a need for 
additional resources, such as access to more timely screening or HPV vaccination programs. To 
evaluate disparities in HGCL incidence, we sought to identify spatial areas with significantly 
elevated HGCL burden in Connecticut, and to determine the salient demographic & 
socioeconomic characteristics associated with high HGCL incidence.  
Materials & Methods: 
In 2008, the Centers for Disease Control and Prevention began to monitor the impact of 
HPV vaccination through population-based surveillance of cervical intraepithelial neoplasia 
grades 2, 2/3 or 3 and adenocarcinoma in situ (CIN2+) conducted by five of the Emerging 
Infections Program sites. At the Connecticut (CT) HPV-IMPACT site, the CT Department of 
Public Health added CIN2+ to the list of reportable diseases statewide, effective January 1, 2008. 
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All 34 pathology laboratories that have served CT residents are in compliance with the reporting 
requirement. These laboratories are regularly contacted to ensure ongoing, complete, and timely 
reporting, and quality assurance protocols are routinely implemented. Pathology laboratories that 
collectively report >80% of cases are routinely audited for completeness. This work has been 
deemed public health surveillance by university, state, and federal institutional review boards 
and thus exempt from the need for human subject approval. 
All reported cases were individually geocoded by residential address to the census tract 
level using the Federal Financial Institutions Examination Council (FFIEC) Geocoding/Mapping 
System database. Previous research has shown that census tract-based measures that describe the 
neighborhoods in which people live reflect important aspects of social context and are important 
for determinants for health23. These geocodes were then matched to American Community 
Survey data for census tract-based measures of race (% black), ethnicity (% Hispanic) and 
poverty (% living below the federal poverty line) for that year of HGCL diagnosis. 
Data for this analysis included the period January 1, 2008–December 31, 2016. The 
number of HGCL cases were tabulated for the 833 census tracts in the state of Connecticut, as 
well as grouped by year and by age at first diagnosis. For women with multiple reports, only the 
first CIN 2+ diagnosis was included in this analysis. Cases during the study time period were 
aggregated by year of diagnosis into three time periods (2008–2010, 2011–2013, 2014–2016) to 
analyze temporal changes in geographic distribution of HGCL cases. 
Spatial analyses were performed using SaTScan v9.6 to identify clusters of census tracts 
in Connecticut having significantly elevated incidence of HGCL compared to the expected 
number of cases for that census tract. A purely spatial analysis using a discrete Poisson model 
and a Monte Carlo simulation using 999 permutations was used to compare the aggregated year 
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groups of case data to the null hypothesis that women diagnosed with HGCLs were equally 
geographically distributed across all census tracts in Connecticut. A cluster was considered to be 
significant if the Monte Carlo simulation yielded a p-value of ≤0.05. Overlapping clusters were 
not permitted for this analysis, and the percent of the population at risk was set to 50%. The input 
parameter for the number of cases was the observed number of HGCL cases per census tract, and 
the population denominator was the predicted number of cases per census tract following 
adjustment for age and year of diagnosis, percent Black population, percent Hispanic population, 
and percent below poverty population using a generalized linear model, assuming the number of 
cases followed a Poisson distribution. Nine different runs of the spatial analysis were performed: 
one for each aggregated year group across all ages, one for each aggregated year group for 
women 21–29 years of age at first diagnosis, and one for each aggregated year group for women 
30–39 years of age at first diagnosis. Geospatial distributions of significant clusters were mapped 
using ArcMap v10.4.1 and shapefiles obtained from the University of Connecticut GIS Data 
Library. 
To evaluate the relationship between the number of women in each census tract with a 
HGCL and fixed covariates, including age and year of primary HGCL diagnosis, and area-based 
measures of proportion Black, Hispanic and below poverty populations per census tract, a mixed 
effects model was constructed. In this model, census tracts were treated as spatially independent. 
A Markov Chain Monte Carlo simulation was used to sample from the posterior distributions 
defined in the model for random effects values of the model, as well as for the coefficients for 
each fixed covariate, to estimate the predicted number of HGCL cases by census tract. Four 
separate mixed effects models were run to assess the success of the model in predicting the 
number of HGCL cases per census tract, given the fixed covariates included in the model. Model 
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1 included age and year at diagnosis, while models 2–4 included age, year and one of the three 
area-based measures of race, ethnicity or poverty. Age was aggregated into two-year groups, and 
area-based measures of race, ethnicity and poverty were scaled by the mean and standard 
deviation of each measure. The likelihood of the predicted incidence values was used to calculate 
goodness-of-fit criteria for each model, including Deviance Information Criterion (DIC) and the 
effective number of parameters (PD), which balances goodness of fit and model complexity. All 
DIC and PD values were compared to the reference model including only age and year. R 
software version 3.4.3 was used for this analysis. 
Results: 
A total of 16,038 women were diagnosed with a high-grade cervical lesion between 
January 1st, 2008–December 31st, 2016 and reported to the Connecticut Emerging Infections 
Program and the Connecticut Department of Public Health. Of these women, 9567 (59.6%) were 
20–29 years of age at their first HGCL diagnosis and 6471 (40.3%) were 30–39 years of age 
(Table 1). Of the 16,038 HGCL cases reported between 2008–2016, 97% were successfully 
matched to a census tract. HGCL cases were reported from 823 of 833 (98%) census tracts with 
annual incidence rates from 2008–2016 ranging from 0–2840 cases per 100,000 (median 1330 
per 100,000).  
Figures 1–3 show the incidence rates by census tract of the observed and adjusted number 
of HGCL cases. After adjusting for age and year of HGCL diagnosis, proportion Black, Hispanic 
and below poverty by census tract, the incidence rates by census tract is more equally spatially 
distributed and no longer show aggregation around urban areas. 
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 There were four significant clusters of HGCL detected using the SaTScan method across 
the aggregated year and age groupings (Table 2). Two significant clusters were detected across 
all age groups: one among the 2008–2010 data (1.1) (Figure 4) and one among the 2014–2016 
data (3.1) (Figure 6). The number of census tracts included in these clusters range from 78 to 91. 
A third significant cluster was detected among the 21–29 year olds in 2008–2010, with 27 census 
tracts included in the cluster (2.1) (Figure 5). The fourth significant cluster was detected among 
the 30–39 year olds in 2014–2016, with 11 census tracts included in the cluster (4.1) (Figure 7). 
All of the census tracts included in cluster 4.1 were also included in cluster 3.1. 
Compared to state estimates for area-based measures of socioeconomic status, the census 
tracts included in clusters 1.1, 2.1 and 3.1 had a lower median % Black population, median % 
Hispanic population and median % population below poverty. The census tracts included in 
cluster 4.1, however, had higher median % Black population, median % Hispanic population and 
median % population below poverty than the respective estimates for the state of Connecticut 
(Table 3). The racial, ethnic and income composition of cluster 3.1 and 4.1 varied significantly, 
even with the clusters overlapping on census tracts and in year group. Clusters 1.1 and 2.1 were 
similar in their area-based measures of socioeconomic status composition, with both falling 
under the state median estimates for all three categories.  
After assessing goodness-of-fit criteria for each mixed effects model, the fixed covariates 
that, when included, yielded the lowest DIC score were age, year and proportion Hispanic per 
census tract, and were therefore the most predictive of the number of HGCL cases per census 
tract (Table 4). The model with the highest DIC score, and was therefore least predictive of the 





Declines in overall incidence of HGCLs, as well as in the age group 21–29 year olds, 
from 2008–2016 is suggestive of an impact from the introduction of the HPV vaccine, as 
previously shown for this age group27. The unchanging incidence of HGCLs in the 30–39 year 
old women in Connecticut is suggestive that women in this group having lagging HPV vaccine 
coverage, were ineligible to receive the vaccine due to age, or received the HPV vaccine 
following HPV infection that caused them to develop a HGCL. With the coverage of the 
nonavalent HPV vaccine for all children under age 18 in Connecticut through the CT Vaccine 
Program, along with proposed legislation for a mandate of HPV vaccination for seventh graders 
in Connecticut, the HPV vaccination coverage in CT should increase to the Healthy People 2020 
goal of 80% coverage. 
The spatial clustering of HGCL cases after adjustment for age, year and area-based 
measures indicates an underlying disparity or phenomenon occurring in those census tracts that 
cannot be explained by the fixed covariates included in the analysis, such as individual level 
sociodemographic characteristics, and abnormally low vaccine coverage. While these clusters 
only span three-year aggregated year groups and do not persist beyond these time periods, the 
significant cluster in central Southern Connecticut, composed largely of 30–39 year old women 
diagnosed with HGCL, indicates a need for continued surveillance of this population of women 
at a state level to assess persistence and socioeconomic composition of these clusters. The high 
median proportions Black, Hispanic and below poverty, as compared to the state medians, in this 
most recent cluster may lead to greater insights into the differences in vaccination or screening 
for cervical cancers that may be driving higher than expected incidence.   
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The high and geographically widespread incidence of high-grade cervical lesions in 
823/833 census tracts in Connecticut between 2008–2016 supports the continued need for 
surveillance. Incidence, prior to adjustment for age and year at diagnosis, and area-based 
measures of race, ethnicity and poverty, is centered largely around the urban areas of 
Connecticut. Following the adjustment for age, year and area-based measures of race, ethnicity 
and poverty, incidence is more evenly distributed across census tracts which is suggestive of the 
salient influence nature that neighborhood level characteristics have on HGCL burden 
distribution through this time period. Potential drivers behind the observed disparate incidence of 
HGCLs across Connecticut include variability in vaccine-uptake by neighborhood level 
sociodemographic characteristics, as well as availability of health insurance and access to 
screening prior to the progression of disease to HGCL.  
The effect of these area-based measures on predicting the number of HGCL cases is 
greatest when using proportion Hispanic, followed by proportion Black and then proportion 
below poverty. While previous studies have indicated the strength of the associations between 
poverty and CIN2+ incidence, the role of race and ethnicity in predicting incidence of HGCL has 
been less clear previously as women who are Black and Hispanic have been shown to have a 
lower risk for the diagnosis of CIN3 when compared to White, non-Hispanic women24. While 
Hispanic populations in the United States have not experienced large declines in the number of 
uninsured individuals since the expansion of Medicaid eligibility, Hispanic women as a sub-
demographic population have seen a greater decline in the number of uninsured and an increase 
in cervical cancer screening rates since Medicaid expansion in 201425,26. This may result in a 
future increase in the number of Pap smears and catching of HPV infection and HGCLs earlier 
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during the natural history of HPV infection, resulting in faster treatment and decreased incidence 
of HGCL beyond 2016. 
Some limitations of this analysis should be noted. The only fixed covariates included in 
the adjustment for the population denominator for SaTScan analysis were those that were 
available, which excluded individual level race, ethnicity and poverty, HPV vaccine coverage by 
census tract, and screening history prior to HGCL diagnosis. Without the availability of HPV 
vaccination, differences in local healthcare systems, or cervical cancer screening data at the 
census tract level, we cannot truly understand what may be driving HGCL incidence at a local 
level. Within the mixed effects, a full model containing all fixed covariates could not be 
performed due to inability of the model to converge from collinearity between area-based 
measures of race and poverty, which may have resulted in an under or overestimate the DIC 
goodness of fit values produced for this analysis with a single area-based measure included. 
Findings for this study may not be generalizable beyond Connecticut. Important strengths of this 
study include robust data collection performed through mandated population-based surveillance 
case ascertainment of women diagnosed with HPV-related precancerous lesions, as well as 
census-tract level information about HGCL incidence.   
Conclusion: 
High HPV vaccination coverage, along with consistent and timely cervical cancer screening 
across all sociodemographic groups of women in CT will best lower incidence of HGCLs. The 
continuation of Medicaid expansion eligibility will be critical for ensuring that women of all 
races, ethnicities and income-levels receive the proper preventive and therapeutic care necessary 
to limit differences in HGCL incidence seen across various sociodemographic groups of women. 
Vaccine impact on age-specific incidence of HGCL may be observed in these findings, however, 
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continued surveillance of HGCL incidence by age and location will be necessary as incidence in 
later age groups is unchanging. Future work in monitoring vaccination at a finer geographic 
level, such as census tract, will be necessary to understand drivers behind differences in HGCL 



























Table 1. Total Number of High-Grade Cervical Lesion Cases, 2008–2016 

















Year Number of HGCL Cases Annual Incidence Rate1 
2008–2010 6189 9100 
2011–2013 5403 7900 
2014–2016 4446 6500 
   
21-29 Years of Age   
2008–2010 3831 5600 
2011–2013 3343 4900 
2014–2016 2393 3500 
   
30-39 Years of Age   
2008–2010 2358 3100 
2011–2013 2060 3000 




Table 2. Relative Risk in Clusters of High-Grade Cervical Lesions, 2008–2016 























Cluster Number Year/Age Group Relative Risk1 p-value 
1.1 2008–2010 All Ages 1.24 0.0016 
2.1 2008–2010 21–29 1.48 0.0260 
3.1 2014–2016 All Ages 1.25 0.0077 
4.1 2014–2016 30–39 2.22 0.0130 
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State 2008–2010 3.3 6.4 6.2 
Cluster 1.1 2008–2010 All Ages 2.7 5.2 4.7 
Cluster 2.1 2008–2010 21–29  2.3 4.1 5.0 
     
State 2011–2013 3.8 7.0 6.4 
     
State 2014–2016 4.0 8.2 6.8 
Cluster 3.1 2014–2016 All Ages 1.2 4.5 5.5 





Table 4. Associations Between HGCL and Area-Based Measures of Race, Ethnicity & Poverty, 

























1 Age, Year 98867.8 456.9 
2 Age, Year, % Below 
Poverty 
98685.6 382.2 
3 Age, Year, % Black 98680.2 358.4 






























Figure 1. Observed and adjusted annual incidence rate per 100,000 of high-grade cervical lesions 
by census tract, 2008-2010. A, Observed IR of high-grade cervical lesions by census tract, 2008-
2010. B, Adjusted incidence rate, which adjusts for age and year at HGCL diagnosis, and area-






























Figure 2. Observed and adjusted annual incidence rate per 100,000 of high-grade cervical lesions 
by census tract, 2011-2013. A, Observed IR of high-grade cervical lesions by census tract, 2011-
2013. B, Adjusted incidence rate, which adjusts for age and year at HGCL diagnosis, and area-






























Figure 3. Observed and adjusted annual incidence rate per 100,000 of high-grade cervical lesions 
by census tract, 2014-2016. A, Observed IR of high-grade cervical lesions by census tract, 2014-
2016. B, Adjusted incidence rate, which adjusts for age and year at HGCL diagnosis, and area-
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